Long-acting cabotegravir for HIV PrEP was licensed to MPP in 2022.

Cabotegravir is the only approved integrase strand transfer inhibitor (INSTI) for long-acting HIV treatment, in combination with rilpivirine. Long-acting cabotegravir has the potential of becoming a key component for other future long-acting regimens for HIV treatment that could be introduced in LMICs. Injectable cabotegravir and rilpivirine for HIV treatment are not currently listed in WHO guidelines.